Document Detail


Will warfarin soon be passé? New approaches to stroke prevention in atrial fibrillation.
MedLine Citation:
PMID:  18594479     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Atrial fibrillation (AF) is the most common cause for thromboembolic stroke. Oral anticoagulation with warfarin is still the most effective therapy in patients with AF, who are at an increased risk for stroke. Nevertheless, warfarin therapy has several limitations; therefore, new anticoagulants like warfarin analogs, thrombin inhibitors, or factor Xa inhibitors have been developed. Some of them are currently being tested in phase III trials in patients with AF. Furthermore, the pathophysiology of prothrombotic endocardial remodeling in fibrillating atria suggests that angiotensin II increases prothrombotic expression of vascular adhesion molecules at the atrial endocardium. Thus, novel anticoagulants or hybrid therapy with a combination of anticoagulants with inhibitors of endocardial remodelling like angiotensin II receptor blockers appear to be attractive future perspective approaches.
Authors:
Matthias Hammwöhner; Andreas Goette
Related Documents :
17123649 - Large recesses associated with left ventricular noncompaction: an unusual presentation ...
10613979 - Anticoagulation in congestive cardiomyopathy: steps toward defining the great unknown.
3272209 - Anticoagulation variability between centres: implications for comparative prosthetic va...
9562269 - Aphagia due to pharyngeal constrictor paresis from acute lateral medullary infarction.
16232019 - Safety of outpatient dalteparin therapy in veterans with mechanical heart valves.
2506849 - Coronary artery vasculitis and myocardial infarction associated with antiphospholipid a...
17397949 - Cholinergic stimulation with pyridostigmine prevents the impairment in ventricular func...
20424449 - First report of the successful use of bosentan in refractory vasospastic angina.
1899409 - Determinants of recurrent ischaemia and revascularisation procedures after thrombolysis...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  52     ISSN:  1533-4023     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-07-22     Completed Date:  2008-11-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  18-27     Citation Subset:  IM    
Affiliation:
Division of Cardiology, University Hospital Magdeburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticoagulants / therapeutic use*
Atrial Fibrillation / complications,  drug therapy*
Factor Xa / antagonists & inhibitors
Fibrinolytic Agents / therapeutic use
Humans
Receptors, Angiotensin / antagonists & inhibitors
Stroke / etiology,  prevention & control*
Thrombin / antagonists & inhibitors
Warfarin / analogs & derivatives*,  therapeutic use*
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Fibrinolytic Agents; 0/Receptors, Angiotensin; 81-81-2/Warfarin; EC 3.4.21.5/Thrombin; EC 3.4.21.6/Factor Xa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatment of coronary spastic angina with a statin in addition to a calcium channel blocker: a pilot...
Next Document:  Therapeutic considerations in applying rate control therapy for atrial fibrillation.